Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong
July 31, 2018
Andrew J. Armstrong MD MSc, Full Professor of Medicine at Duke University, Durham, NC. He is a clinical and translational researcher focused on drug development and biomarker studies in prostate and kidney cancer. This research includes prognostic and predictive biomarkers, circulating tumor cell biology, and how cancer spreads (metastasis). He oversees multiple clinical trials of new therapies for patients ranging from new hormonal and chemotherapies to new immunotherapies and molecularly targeted agents. Additionally, Dr. Armstrong is an Associate Professor of Medicine, Associate Professor in Pharmacology and Cancer Biology and Associate Professor in Surgery
Alicia Morgans, MD, MPH
Studies Referenced in this Interview:
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine 2014;371:1028-38.
Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
PROPHECY - A Prospective Trial of Circulating Tumor Cell AR-V7 Detection in mCRPC with Abiraterone or Enzalutamide